Could a Simple Blood Test Predict a Heart Event in Type 2 Diabetes?

Could a routine blood sample someday reveal cardiovascular danger that cholesterol, blood pressure, and HbA1c do not fully capture? New research suggests that epigenetic cardiovascular risk prediction could offer a new way to identify people with type 2 diabetes who face a higher short-term risk of major cardiovascular events. Instead of looking only at conventional risk factors, researchers measured DNA methylation patterns in blood and developed models designed to detect biological signals associated with future events. The early results are promising. However, these models remain investigational and are not ready to replace established cardiovascular risk assessment.

Table of Contents

• How epigenetic testing could help predict cardiovascular risk
• What the new DNA methylation models found
• How epigenetic testing compares with current risk assessment
• Could a blood test eventually change diabetes care?
• Conclusion
• Frequently asked questions

How Epigenetic Testing Could Help Predict Cardiovascular Risk

Epigenetics refers to biological changes that influence how genes function without changing the underlying DNA sequence. One of the best-studied epigenetic mechanisms is DNA methylation, which involves chemical marks attached to specific locations in DNA.

These methylation patterns can reflect a combination of genetics, aging, environmental exposures, smoking, metabolic health, and other influences. Consequently, researchers have become interested in whether blood DNA methylation could serve as a measurable record of cardiovascular risk.

A 2026 study published in Diabetes Care examined this possibility in 305 people with type 2 diabetes from the TOSCA.IT study. At baseline, none had previous cardiovascular disease. Researchers analyzed DNA methylation in peripheral blood mononuclear cells and followed cardiovascular outcomes. The study examined whether blood-based DNA methylation models could improve short-term cardiovascular risk prediction.

During five years of follow-up, 81 participants experienced a major adverse cardiovascular event, or MACE. The study defined MACE as all-cause death, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization. The remaining 224 participants served as event-free controls.

Researchers then used machine-learning methods to identify methylation patterns associated with future cardiovascular events. Rather than relying on one biomarker, the approach combined information from multiple CpG sites, which are locations in DNA where methylation commonly occurs.

This epigenetic approach to cardiovascular risk assessment differs from measuring a single laboratory marker such as LDL cholesterol. In effect, researchers are asking whether many small molecular signals can collectively reveal cardiovascular vulnerability that conventional measurements may miss.

What the New DNA Methylation Models Found

The investigators developed five DNA methylation models using different levels of adjustment for clinical and biological variables. Each model ultimately contained between 22 and 26 CpG predictors.

The study population was divided into a training group containing 80% of participants and an internal test group containing the remaining 20%. Importantly, the models were evaluated in that internal test set rather than simply being judged by how well they fit the data used to develop them.

Performance was striking. In the internal test cohort, the five models produced receiver operating characteristic area under the curve, or ROC-AUC, values ranging from 0.915 to 0.937. Their precision-recall AUC values ranged from 0.866 to 0.940.

At the study’s selected classification threshold, sensitivity was 88.24%, while specificity ranged from 95.56% to 97.78%. Negative predictive values were above 95%, and positive predictive values ranged from 88.24% to 93.75%.

Those numbers suggest strong discrimination within this particular study population. However, they should not be interpreted as proof that a commercial blood test could achieve the same performance in everyday practice.

The test cohort included only 62 participants, including 17 who experienced MACE. Therefore, larger external studies involving more diverse populations will be critical before these results can support routine clinical use.

How Epigenetic Testing Compares With Current Risk Assessment

Clinicians already use age, smoking status, blood pressure, lipid levels, kidney function, glycemic measures, and medical history when estimating cardiovascular risk. Tools such as SCORE2-Diabetes and PREVENT-CVD combine several of these factors to support clinical decision-making.

Yet cardiovascular risk prediction in type 2 diabetes remains challenging. Diabetes In Control has previously reviewed how diabetes risk stratification can help clinicians identify high-risk patients and tailor treatment. The site has also examined why cardiovascular prediction models in people with diabetes may not perform equally well across every patient population.

DNA methylation-based risk prediction could eventually add another layer to that assessment rather than replacing conventional cardiovascular risk tools.

Supporting that idea, a separate 2025 study examined 752 people with newly diagnosed type 2 diabetes. Researchers identified 461 DNA methylation sites associated with incident macrovascular events and created an 87-site methylation risk score. The study is available through PubMed.

That methylation score achieved an AUC of 0.81. When researchers combined it with clinical risk factors, the AUC increased to 0.84. By comparison, several conventional and polygenic risk approaches in that analysis produced AUCs ranging from 0.54 to 0.62.

Taken together, the studies strengthen the case for investigating DNA methylation as a cardiovascular biomarker. Still, their specific methylation signatures differed, which highlights an important challenge. A useful clinical test will need to perform consistently across populations, laboratories, and testing platforms.

Could a Blood Test Eventually Change Diabetes Care?

The attraction of a blood-based epigenetic test is easy to understand. Clinicians could potentially identify a patient whose conventional risk profile appears moderate but whose molecular profile suggests greater short-term cardiovascular vulnerability.

In theory, that information could encourage closer monitoring or more intensive attention to modifiable cardiovascular risk factors. However, prediction alone does not prove that testing improves outcomes.

Before epigenetic cardiovascular risk tools enter routine diabetes care, researchers must show that these models perform well in large and diverse external populations. Studies will also need to establish standardized laboratory methods, practical thresholds, cost-effectiveness, and whether acting on the results actually prevents cardiovascular events.

Moreover, current evidence-based cardiovascular prevention should not wait for epigenetic testing. Blood pressure management, lipid lowering, smoking cessation, physical activity, weight management, kidney assessment, and appropriate glucose-lowering therapies with cardiovascular benefits remain central to reducing risk.

Emerging biomarkers may eventually refine those decisions. For example, Diabetes In Control has also examined suPAR as a possible marker of cardiovascular risk, illustrating the broader effort to identify risk that conventional measurements may not fully capture.

For now, DNA methylation should be viewed as a promising research tool rather than a clinical shortcut. Patients concerned about their cardiovascular risk should discuss established assessment and prevention strategies with their healthcare professional.

Conclusion

Blood-based DNA methylation models offer an intriguing new approach to cardiovascular risk assessment in type 2 diabetes. Recent research found strong discrimination for major cardiovascular events over five years, while earlier work also showed that methylation scores could add predictive information beyond conventional risk factors.

Nevertheless, these findings require broader external validation. The current studies do not establish DNA methylation testing as a routine cardiovascular screening tool.

The most likely future role may be complementary. Rather than replacing established cardiovascular risk factors, DNA methylation testing could eventually help clinicians identify risk not fully captured by conventional assessments and refine preventive strategies for selected patients.

Frequently Asked Questions

What is epigenetic cardiovascular risk prediction?

It uses epigenetic markers, such as DNA methylation patterns measured in blood, to estimate a person’s likelihood of experiencing future cardiovascular events.

Can DNA methylation predict a heart attack?

Research suggests DNA methylation patterns can help distinguish groups at higher and lower cardiovascular risk. However, they cannot predict with certainty whether an individual will have a heart attack.

Is there a routine blood test for epigenetic cardiovascular risk in diabetes?

Not currently. The DNA methylation models discussed in recent studies remain investigational and require further validation before routine clinical adoption.

Could epigenetic testing replace standard cardiovascular risk scores?

Current evidence does not support replacing established risk assessment. Instead, DNA methylation could eventually complement clinical risk factors and improve cardiovascular risk stratification.

Why could this research matter for people with type 2 diabetes?

People with type 2 diabetes can have substantial cardiovascular risk that is not fully captured by individual conventional markers. Better prediction could eventually help clinicians identify higher-risk patients earlier and personalize preventive strategies.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.